ClinicalTrials.gg
Active, not recruitingNCT05996523Updated Jun 23, 2026Results posted

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

A Phase 2 interventional study of PRGN-2009 and Pembrolizumab in Oropharyngeal Squamous Cell Carcinoma (SCC), sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI) — 8 open to participants now, 17 under way, 4 of them phase 3. Squamous Cell Carcinoma of Head and Neck · National Cancer Institute (NCI).

Enrollment
48th of 70
26 · median 40
Started
2023
with 1 other
Phase 2
34 of 76
5 open now
Primary completion
2025-05
later than 5 of 16 live
Registered
70th of 76
by date

Among the 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI), this one is the 48th largest by enrollment of the 70 interventional ones that give a count, is one of 2 that started in 2023, is one of 34 in phase 2, reaches primary completion later than 5 of the 16 other live ones, and was the 70th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

8 of the 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against these cancers. Researchers want to find out if they might work better when used together.

Objective:

To test pembrolizumab combined with PRGN-2009 in people with HPV-positive cancers in and around the mouth.

Eligibility:

Adults aged 18 and older newly diagnosed with HPV-positive cancers in and around the mouth.

Design:

Participants will be screened. They will have a physical exam with blood tests. They will have imaging scans. They may need to have a biopsy: A sample of tissue will be taken from the tumor.

PRGN-2009 is given as an injection under the skin. Pembrolizumab is given through a tube attached to a needle inserted into a vein in the arm.

Participants will have at least 3 clinic visits: At the first, they will receive both the drug and the vaccine; 15 days later, they will receive a second shot of the vaccine. At the third visit, about 1 week after the second, they will have follow-up tests.

During these visits, participants will give samples of blood, urine, and saliva. Imaging scans and biopsies will be repeated. They will have tests of their heart function.

Participants may opt to return for another follow-up visit about 1 month after their second dose of the vaccine.

Participants will have follow-up contacts by phone 3 and 6 months after starting the study. The calls will continue once a year for 5 years.

Read the detailed description

Background

-Human papilloma virus-associated oropharyngeal cancer (HPV-OPC) is the most common HPV-associated malignancy in the United States, with an increasing incidence. Although the prognosis for stage I HPV-OPC is favorable, about 20 percent of patients with stage II

disease and 35 percent of patients with stage III disease will die within four years.

  • The standard-of-care primary treatment for HPV-OPC without distant metastasis is definitive concurrent chemoradiotherapy (primarily) or surgery (which may be followed by adjuvant chemoradiotherapy).
  • Neoadjuvant/induction immunotherapy is in clinical trials aiming to induce antigen-specific immunity prior to primary treatment and to reduce the risk of disease relapse. Pembrolizumab, an anti-PD-1 monoclonal antibody that is Food and Drug Administration (FDA)-approved for first-line treatment of recurrent/metastatic head and neck squamous cell cancer (HNSCC) has been used in these trials and shown to be safe and active.
  • PRGN-2009 is an anti-HPV immunotherapeutic vaccine. It has demonstrated induction of HPV antigen-specific responses and tumor growth inhibition in pre-clinical models of HPV-associated malignancy, with improved anti-tumor efficacy upon addition of T-cell immune checkpoint blockade. In a Phase I/II trial at the National Cancer Institute (NCI) it has demonstrated excellent safety and tolerability as monotherapy or in combination with checkpoint blockade in recurrent/metastatic disease but also as monotherapy in neoadjuvant/induction context for HPV-OPC.

Objective:

-To determine if the use of PRGN-2009 with pembrolizumab in participants with p16-positive OPC can result in a >= 2-fold increase in cluster of differentiation 3 (CD3+) tumor infiltrating T cells post treatment compared with pre-treatment.

Eligibility:

  • Age >= 18 years.
  • Pathologically confirmed newly diagnosed Stage I (T1, T2; N1), II or III p16-positive OPC.

Design:

  • This is a Phase II study to evaluate the effect of PRGN-2009 and pembrolizumab before definitive treatment in subjects with p16-positive OPC.
  • Participants will receive PRGN-2009 and pembrolizumab prior to definitive treatment.
  • Participants will receive two doses of PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart, and one dose of pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose.
  • Up to 20 evaluable participants will be enrolled.
03

Conditions studied

  • Oropharyngeal Squamous Cell Carcinoma (SCC)

Keywords

  • HPV16/18
  • PD-1 inhibitor
  • Monoclonal Antibody
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have or histologically confirmed newly diagnosed stage I (T1,2 N1), II or III p16-positive oropharyngeal squamous cell carcinoma (SCC) planned for definitive therapy (surgery or chemoradiotherapy).
  • Subjects must have , per (RECIST) 1.1.
  • Age >=18 years.
  • [ECOG] performance status \<= 2.
  • Adequate hematologic function at screening, as follows:

    • (ANC) >=1 x 10\^9/L;
    • (Hgb) >= 9 g/dL;
    • >= 75,000/microliter.
  • Adequate renal and hepatic function at screening, as follows:

    • Serum creatinine \<= 1.5 x (ULN) OR measured or calculated >= 40 mL/min for participant with creatinine levels > 1.5 x ULN ( [GFR] can also be used in place of creatinine or CrCl);
    • Total \<= 1.5 x ULN OR in subjects with Gilbert's syndrome, a total bilirubin \<= 3.0 x ULN;
    • (ALT) and aspartate aminotransferase (AST) \<= 2.5 x ULN, unless liver are present, then values must be \<= 3 x ULN.
  • Participants serologically positive for (HIV) , or are eligible if the viral loads are undetectable by quantitative polymerase chain reaction (PCR). Note: HIV positive participants must have >= 200 cells/mm\^3 at enrollment, be on stable antiretroviral therapy for at least 4 weeks and have no reported opportunistic infections or Castleman's disease within 12 months prior to enrollment.
  • Women of (WOCBP) must agree to use effective (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for at least 4 months following the last dose of pembrolizumab.
  • Participants must be willing to undergo two research on this study.
  • Ability of participant to understand and the willingness to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

  • Participants with prior drug, , chemotherapy, immunotherapy, or any prior radiotherapy (except for palliative bone directed therapy) within the past 4 weeks prior to the first drug administration. Participants may continue hormonal therapy in the setting of a definitively treated cancer (e.g., breast).
  • Major surgery within 28 days prior to the first drug administration (minimally invasive procedures such as diagnostic are permitted).
  • Pregnant individuals as evaluated by a positive serum or urine Beta-human chorionic gonadotropin (hCG) at screening
  • Active disease that might deteriorate when receiving an immunostimulatory agent with the exception of:

    • Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroidism or other mild autoimmune disorders not requiring treatment.
    • Administration of through a route known to result in a minimal systemic exposure (topical, intranasal, intraocular, or inhalation).
  • Systemic (intravenous or oral) glucocorticoid (except for physiologic doses of corticosteroids, i.e., \<= the equivalent of prednisone 10 mg/day) or other immunosuppressors such as azathioprine or cyclosporin A, are excluded because of potential immune suppression. These treatments must be discontinued at least 1 week prior to enrollment for recent short course use (\<= 14 days). Glucocorticoids as premedication for contrast-enhanced studies is allowed prior to enrollment and on study.
  • Participants with a prior or concurrent whose natural history or treatment that has potential to interfere with the safety or efficacy assessment of the regimen.
  • Prior allogenic tissue/solid organ transplant.
  • Participants with pulse oximetry \< 92% on room air at screening.
  • Uncontrolled intercurrent illness that would limit compliance with study requirements suggested by medical history, physical examination or standard clinical assessments such as imaging and laboratory studies.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Arm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg Intravenous

    PRGN 5x10\^11 Viral Particles (VP) subcutaneous (SC) plus pembrolizumab 200mg intravenous (IV) as induction/ neoadjuvant therapy

    Biological: PRGN-2009 · Drug: Pembrolizumab · Diagnostic Test: EKG · Diagnostic Test: CT · Diagnostic Test: PET scan · Diagnostic Test: MRI · Procedure: Biopsy

Interventions

  • BiologicalGorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 VaccineStudies of Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 VaccineGorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart

  • Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose

    Also known as: Keytruda

  • Diagnostic testEKG

    Baseline, completion visit, and safety follow-up visit.

    Also known as: Electrocardiogram

  • Diagnostic testCT

    Screening and baseline (neck and chest), and completion visit (neck).

    Also known as: Computed tomography

  • Diagnostic testPET scan

    Screening and baseline (neck and chest).

    Also known as: Positron emission tomography

  • Diagnostic testMRI

    Screening and baseline (neck and chest), and completion visit (neck).

    Also known as: Magnetic resonance imaging

  • ProcedureBiopsy

    Baseline and completion visit.

    Also known as: Bx

06

What researchers measure

Primary outcomes

  1. Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment.

    CD3+ tumor infiltrating T cells post treatment compared with pre-treatment reported with a 95% confidence interval assessed by multiplex CD3+ tumor infiltrating lymphocytes assessed by multiplex immunofluorescence from the surgical/ biopsy tissue collected pre- and post-treatment. The percentage of participants with doubling of baseline CD3+ tumor infiltrating lymphocytes will be provided as well as the 95% confidence interval. The CD3 cells are assessed by multiplex immunofluorescence in the biopsies. Doubling is the desired outcome.

    Time frame: Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment

Secondary outcomes

  1. Overall Survival at 3 Years Compared With Historical Cohort

    Assess if PRGN-2009 plus pembrolizumab results in significantly prolonged survival at three years as compared to the expected 80% three-year historical survival in p16-positive oropharyngeal cancer (OPC) participants. Three-year overall survival will be measured using a Kaplan-Meier curve and will be compared descriptively with the historical benchmark. Participants who receive two doses of PRGN-2009 and the single dose of pembrolizumab and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

    Time frame: 3 years

  2. Overall Survival at 3 Years

    Overall survival was assessed using the Kaplan-Meier method and is defined as the time from the date of first treatment to the date of death (any cause). Participants who receive two doses of PRGN-2009 and the single dose of pembrolizumab and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

    Time frame: 3 years

  3. Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term

    Number of treatment-related serious adverse events of Grades 1, 2, 3, 4 and/or 5 along with the AE term. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

    Time frame: From baseline up to 28 days after last treatment, up to 2 months.

  4. Percentage of 2-fold Increase in Cluster of Differentiation (CD3+) Tumor Infiltrating Lymphocytes (TILs) Post-treatment Compared to Pre-treatment in This Trial Compared to Participants Receiving PRGN2009 in Study NCT04432597

    Percentage of 2-fold increase in CD3+ Tumor Infiltrating Lymphocytes (TILs) by multiplex immunofluorescence post-treatment compared to pre-treatment in participants receiving PRGN2009 plus pembrolizumab in this trial as compared to that in participants receiving PRGN2009 monotherapy in study NCT04432597. Results of the primary endpoint of this study (Proportion of 2-fold increase in CD3+ Tumor Infiltrating Lymphocytes (TILs) by multiplex immunofluorescence post-treatment compared to pre-treatment) were compared with the same in participants in trial NCT04432597 (PRGN-2009 monotherapy). The two percentages will be compared descriptively and reported with a 95% confidence interval.

    Time frame: Pre-Treatment (Baseline) and anytime between Week 4 to 5 post treatment

  5. Relapse Free Survival (RFS) Rate at 3 Years

    Relapse free survival was assessed using the Kaplan-Meier method and is defined as the time from completion of standard chemoradiation to the date of disease recurrence or death (any cause) whichever comes first. Participants who receive two doses of PRGN-2009 and the single dose of pembrolizumab and go on to receive standard definitive therapy will be evaluable for relapse-free-survival assessment.

    Time frame: 3 years

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

    Time frame: Adverse Events were monitored/assessed from the time of first drug administration through 28 days after the last drug administration up to 2 months

07

Results

Posted Jun 23, 2026

Participant flow

Participant flow — Overall Study
MilestoneEnrolled But Not TreatedArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg Intravenous
Started422
Completed021
Not completed41
Withdrew: Ineligible40
Withdrew: Physician decision01

Outcome measures

PrimaryPercentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment.

CD3+ tumor infiltrating T cells post treatment compared with pre-treatment reported with a 95% confidence interval assessed by multiplex CD3+ tumor infiltrating lymphocytes assessed by multiplex immunofluorescence from the surgical/ biopsy tissue collected pre- and post-treatment. The percentage of participants with doubling of baseline CD3+ tumor infiltrating lymphocytes will be provided as well as the 95% confidence interval. The CD3 cells are assessed by multiplex immunofluorescence in the biopsies. Doubling is the desired outcome.

Time frame:
Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment
Reported as:
Number · percentage of participants
Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment.
percentage of participantsArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg Intravenous
Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment.93.8 (71.7 to 99.7)
SecondaryOverall Survival at 3 Years Compared With Historical Cohort

Assess if PRGN-2009 plus pembrolizumab results in significantly prolonged survival at three years as compared to the expected 80% three-year historical survival in p16-positive oropharyngeal cancer (OPC) participants. Three-year overall survival will be measured using a Kaplan-Meier curve and will be compared descriptively with the historical benchmark. Participants who receive two doses of PRGN-2009 and the single dose of pembrolizumab and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryOverall Survival at 3 Years

Overall survival was assessed using the Kaplan-Meier method and is defined as the time from the date of first treatment to the date of death (any cause). Participants who receive two doses of PRGN-2009 and the single dose of pembrolizumab and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryNumber of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term

Number of treatment-related serious adverse events of Grades 1, 2, 3, 4 and/or 5 along with the AE term. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

Time frame:
From baseline up to 28 days after last treatment, up to 2 months.
Reported as:
Number · Adverse events
Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term
Adverse eventsGrade 1Grade 2Grade 3Grade 4Grade 5
Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term00000
SecondaryPercentage of 2-fold Increase in Cluster of Differentiation (CD3+) Tumor Infiltrating Lymphocytes (TILs) Post-treatment Compared to Pre-treatment in This Trial Compared to Participants Receiving PRGN2009 in Study NCT04432597

Percentage of 2-fold increase in CD3+ Tumor Infiltrating Lymphocytes (TILs) by multiplex immunofluorescence post-treatment compared to pre-treatment in participants receiving PRGN2009 plus pembrolizumab in this trial as compared to that in participants receiving PRGN2009 monotherapy in study NCT04432597. Results of the primary endpoint of this study (Proportion of 2-fold increase in CD3+ Tumor Infiltrating Lymphocytes (TILs) by multiplex immunofluorescence post-treatment compared to pre-treatment) were compared with the same in participants in trial NCT04432597 (PRGN-2009 monotherapy). The two percentages will be compared descriptively and reported with a 95% confidence interval.

Time frame:
Pre-Treatment (Baseline) and anytime between Week 4 to 5 post treatment
Reported as:
Number · percentage of participants
Percentage of 2-fold Increase in Cluster of Differentiation (CD3+) Tumor Infiltrating Lymphocytes (TILs) Post-treatment Compared to Pre-treatment in This Trial Compared to Participants Receiving PRGN2009 in Study NCT04432597
percentage of participantsArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg Intravenous
Participants receiving PRGN2009 plus pembrolizumab with 2-fold increase in CD3+ TIL93.8 (71.7 to 99.7)
Participants receiving PRGN2009 in trial NCT04432597 with 2-fold increase in CD3+ TIL12.5 (3.5 to 36.0)
SecondaryRelapse Free Survival (RFS) Rate at 3 Years

Relapse free survival was assessed using the Kaplan-Meier method and is defined as the time from completion of standard chemoradiation to the date of disease recurrence or death (any cause) whichever comes first. Participants who receive two doses of PRGN-2009 and the single dose of pembrolizumab and go on to receive standard definitive therapy will be evaluable for relapse-free-survival assessment.

Time frame:
3 years

Results for this outcome have not been posted.

Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

Time frame:
Adverse Events were monitored/assessed from the time of first drug administration through 28 days after the last drug administration up to 2 months
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
ParticipantsArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg Intravenous
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)21

Adverse events

Collected over All-Cause Mortality is monitored/assessed from the time of first drug administration through the date of death (any cause), an average of 14 months. Adverse Events were monitored/assessed from the time of first drug administration through 28 days after the last drug administration, up to 2 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg Intravenous0/22 (0%)0/21 (0%)21/21 (100%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg Intravenous
Injection site reactionGeneral disorders17/21
Flu like symptomsGeneral disorders10/21
FatigueGeneral disorders6/21
NauseaGastrointestinal disorders6/21
Dry mouthGastrointestinal disorders5/21
DysphagiaGastrointestinal disorders3/21
Oral painGastrointestinal disorders3/21
ConstipationGastrointestinal disorders2/21
HoarsenessRespiratory, thoracic and mediastinal disorders2/21
HypokalemiaMetabolism and nutrition disorders2/21

Baseline characteristics

Data collected for all enrolled participants is reported in baseline characteristics.

Age, Categorical
Age, Categorical(Participants)Enrolled But Not TreatedArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg IntravenousTotal
<=18 years000
Between 18 and 65 years21517
>=65 years279
Age, Continuous
Age, Continuous(years)Enrolled But Not TreatedArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg IntravenousTotal
Mean65.25 ± 7.6362.27 ± 8.8962.73 ± 8.64
Sex: Female, Male
Sex: Female, Male(Participants)Enrolled But Not TreatedArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg IntravenousTotal
Female011
Male42125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enrolled But Not TreatedArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg IntravenousTotal
Hispanic or Latino011
Not Hispanic or Latino42024
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enrolled But Not TreatedArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg IntravenousTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American156
White31619
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)Enrolled But Not TreatedArm 1/PRGN 5x10^11 Viral Particles Subcutaneously Plus Pembrolizumab 200mg IntravenousTotal
United States42226
08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All collected individual participant data (IPD) will be shared. All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data from this study may be requested from other researchers no sooner than 3 years after the completion of the primary endpoint. Genomic data is available once genomic data is uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.

Access criteria: Data from this study may be requested by contacting the principal investigator (PI). Genomic data is made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2025, 18 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 18 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Aug 18, 2023
StartActual
Nov 7, 2023
Primary completionActual
May 22, 2025
CompletionEst.
Jul 16, 2030
Results first posted
Jun 23, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05996523
Responsible party
Charalampos Floudas, MD, DMSc, MS (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted
Aug 18, 2023
Start date
Nov 7, 2023
Primary completion
May 22, 2025
Completion
Jul 16, 2030 (estimated)
Results posted
Jun 23, 2026
Last update
Jun 23, 2026

Study contacts

Charalampos Floudas, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine

Start the discussion